---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Natural history, survival, and mortality"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Natural history, survival, and mortality. Topics: Chronic course and recurrence after remission: 2026 international guideline; Predictors of prolonged disease duration: 2026 international guideline; Remission rates at years 1, 5, and 20: targeted literature review; Remission and relapse clusters in chronic urticaria: electronic health record cohort of 112,443 adults; 9 further topics. 13 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Chronic course and recurrence after remission: 2026 international guideline

> “Chronic urticaria (CU) is defined as the occurrence of wheals, angioedema, or both for more than 6 weeks. CU can come with daily, or almost daily, signs and symptoms, or an intermittent/recurrent course.”
> “CSU episodes may recur after months or years of full remission”
> “Since the severity of urticaria may fluctuate, and spontaneous remission may occur at any time, it is also recommended to re‐evaluate the necessity for continued or alternative drug treatment every three to 6 months.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.3-2"></a>

### Predictors of prolonged disease duration: 2026 international guideline

> “In CSU, disease duration, disease activity, and response to treatment are linked to clinical characteristics and laboratory markers.”
> “For example, the presence of concomitant CIndU, high disease activity, elevated CRP and/or the presence of angioedema are indicative for a prolonged duration of CSU and suboptimal response to antihistamine treatment”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.1.3-3"></a>

### Remission rates at years 1, 5, and 20: targeted literature review

> “The objectives of this targeted literature review were to identify evidence on the clinical course of CSU, including remission rates, and to estimate cumulative remission rates for different time points.”
> “Ten publications were included in this review. The proportion of patients achieving remission within year 1 ranged from 21 to 47%, while reported remission rate estimates at year 5 were 34% and 45%. Based on calculated 4-weekly remission rates, cumulative remission estimates ranged from 9 to 38% at year 1, from 29 to 71% at year 5 and from 52 to 93% at year 20. Cumulative weighted average estimates for the proportion of patients remitting at years 1, 5 and 20 were 17%, 45% and 73%, respectively.”
> “However, data sources differed in terms of definitions of disease severity and remission, as well as in conclusions on influencing factors.”
> “The average disease duration in CSU has been estimated to be 5 years, although it may persist longer in severe cases”

Source: [Balp et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8776966/)

<a id="topic-2.2.1.3-4"></a>

### Remission and relapse clusters in chronic urticaria: electronic health record cohort of 112,443 adults

> “Adults with a CU diagnosis and confirmation CU diagnosis/CU-related treatment at least 6 weeks later were identified in the Optum® de-identified Electronic Health Record dataset (2007–2018). Active CU was a period during which a patient was not in clinical remission. Clinical remission was defined as at least 12 months without CU diagnosis and/or treatment. Relapse was defined as having a CU diagnosis and/or treatment following clinical remission.”
> “The 112,443 patients were grouped into four clusters. Cluster 1 ( N = 36,690 [32.6%]) had the shortest median time to clinical remission (4.1 months) and lowest relapse rate (38.0%). Cluster 2 ( N = 29,834 [26.5%]) reached clinical remission later (10.0 months), with a higher relapse rate (52.3%). Clusters 3 ( N = 24,093 [21.4%]) and 4 ( N = 21,826 [19.4%]) had the longest median times to clinical remission (33.8 and 44.6 months) and highest relapse rates (75%).”

Source: [Balp et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11971071/)

<a id="topic-2.2.1.3-5"></a>

### Remission of chronic urticaria: national sample cohort with 10-year follow-up

> “Patients with new-onset urticaria were identified from the National Health Insurance Service-National Sample Cohort data.”
> “The 10-year cumulative incidence rate of urticaria for the general population was 4.9% and that of chronic urticaria among patients with new-onset urticaria was 7.8%. Remission rates of chronic urticaria were 52.6% at 1 year and 88.9% at 5 years.”
> “Remission was achieved in the majority of patients with chronic urticaria regardless of demographic characteristics or accompanying thyroid disease.”

Source: [Eun et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/29945815/)

<a id="topic-2.2.1.3-6"></a>

### Remission of chronic urticaria: 329 Korean participants in three university hospitals

> “Total 329 Korean patients with CU, who had follow-ups more than 6 months after diagnosis during a 7-year period in the department of dermatology in three university hospitals were enrolled.”
> “The proportion recovered in 1, 3, and 5 years after the onset of CU was 10.8%, 18.8%, and 32.9%, respectively. The mean duration of CU was 6.3 years.”

Source: [Chung et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7992631/)

<a id="topic-2.2.1.3-7"></a>

### Remission in children with chronic urticaria: 77 children followed for at least 48 months

> “We evaluated 77 children diagnosed with CU, who were monitored for at least 48 months.”
> “Remission was defined as having no symptoms without treatment for more than 1 year.”
> “The remission rates at 6 months, 1 year, 2 years, 3 years, and 4 years after symptom onset were 22.1%, 40.3%, 52.0%, 63.7%, and 70.2%, respectively, for children with CU. For children with CSU, these values were 23.4%, 43.7%, 56.2%, 68.7%, and 75.0%, respectively.”

Source: [Kim et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8724829/)

<a id="topic-2.2.1.3-8"></a>

### Remission in children with chronic urticaria: 92 children aged 4 to 15 years

> “Children 4 to 15 years of age with CU were investigated with a complete blood cell count, erythrocyte sedimentation rate, antinuclear antibody titer, complement CH50 level, thyroid studies, autologous serum skin test, skin-prick tests, food challenges, and stool examination for parasites.”
> “In all, 92 children (53.3% female) with CU were recruited and followed up for a median duration of 4.3 years (range 2.5-5.8 years).”
> “Remission rates at 1, 3, and 5 years after the onset of CU symptoms were 18.5%, 54%, and 67.7%, respectively.”

Source: [Chansakulporn et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25023899/)

<a id="topic-2.2.1.3-9"></a>

### Disease duration: physician-diagnosed CSU in a 2019 United States survey

> “To estimate the burden, clinical profile, and prevalence of diagnosed CSU in the United States.”
> “Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS).”
> “The mean (SD) disease duration was 11.0 (12.6) years.”

Source: [Soong et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12296495/)

<a id="topic-2.2.1.3-10"></a>

### All-cause mortality: propensity score-matched electronic health record cohort, TriNetX

> “Chronic spontaneous urticaria (CSU), a common and debilitating disease, is widely held not to be life limiting, but the mortality of CSU has not been investigated.”
> “This was a retrospective population-based cohort study of electronic health records of 272,190 adult patients with CSU and 12,728,913 controls without urticaria from the US collaborative network TriNetX.”
> “The study included 264,680 propensity score–matched patients with CSU (mean [SD] age = 47.5 [19.8] years; 71.5% female) and a corresponding number of controls without urticaria. Patients with CSU had higher 3-month (hazard ratio [HR] 2.10, 95% CI 1.97-2.22), 1-year (HR 1.77, 95% CI 1.71-1.83), and 5-year (HR 1.69, 95% CI 1.65-1.73) all-cause mortality (all P < .0001).”
> “The risk of mortality appeared to be more pronounced in White and younger patients with CSU.”
> “CSU is associated with increased mortality likely due to comorbidities, especially suicide, and effective CSU treatment may reduce mortality. These findings should be investigated in additional studies and in other populations.”

Source: [Kolkhir et al. (2025)](https://doi.org/10.1016/j.jaci.2024.11.036)

<a id="topic-2.2.1.3-11"></a>

### All-cause mortality by treatment exposure, including oral corticosteroids

> “All-cause mortality rates at 5 years were significantly lower in patients treated with second-generation H1 antihistamines versus untreated patients (1.0% vs 2.3%; HR 1.84, P < .0001) and omalizumab-treated patients versus antihistamine-treated patients (0.7% vs 2.6%; HR 3.99, P = .0003).”
> “In a descriptive analysis, CSU treatment with oral corticosteroids and cyclosporine A was linked to the highest mortality rates across all time points, ie, 3 months, 12 months, and 60 months (0.90%, 2.43%, and 7.73% and 3.01%, 3.01%, and 4.52%, respectively), followed by sgAHs (0.48%, 1.13%, and 3.24%) and omalizumab (0.66% at all time points).”

Source: [Kolkhir et al. (2025)](https://doi.org/10.1016/j.jaci.2024.11.036)

<a id="topic-2.2.1.3-12"></a>

### Mortality analysis limitations stated by the authors

> “Limitations of our study, inherent to the retrospective observational design and studies based on patient EHRs, include underdiagnosis, overdiagnosis, misdiagnosis, unmeasured or uncontrolled confounders, self-selection, and reverse causality.”
> “Also, no causal inferences can be drawn as TriNetX does not provide the capability to identify the specific cause of death recorded in the EHRs.”

Source: [Kolkhir et al. (2025)](https://doi.org/10.1016/j.jaci.2024.11.036)

<a id="topic-2.2.1.3-13"></a>

### Mortality association in the 2026 international guideline

> “Recent studies suggested an association between CSU and increased mortality, especially due to suicide, likely linked to its comorbidities”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
